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S238 Oral PresentationsTable. Patient demographics and out of pocket costs for first
3 months after allogeneic HCTPatient characteristics N 5 25
Median patient age (range) 44 (24-71) years
Non-Hispanic White race 24 (96%)
Residence >50 miles from HCT center 12 (48%)
Needed temporary move to HCT center 12 (48%)
Median annual pre-tax income at study
enrollment (range)$65,000 (18,500-150,000)Household income reduced due to illness 20 (80%)
Diagnosis
Acute leukemia/MDS 22 (88%)
Other 3 (12%)Donor type
Related 10 (40%)
Unrelated/UCB 15 (60%)Conditioning intensity
Myeloablative 12 (48%)
Non-myeloablative/RIC 13 (52%)Out-of-pocket costs N 5 15
Median costs (inter-quartile range)
Temporary lodging $2,865 (1,126-3,972)
Transportation $220 (162-576)
Food $701 (301-1,172)
Uncovered medical expenses $507 (250-1,157)
Other $180 (38-1,222)Median miles driven per day (range) 24 (2-96)95
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Arrhythmias during hematopoietic stem cell transplantation may
impact morbidity and mortality. Prior studies report 12-23% of
older patients experience transplant arrhythmias, though the impact
on mortality and overall survival is not clear. Results of a retrospec-
tive analysis of 1255 autologous or allogenic stem cell transplanta-
tions in 1178 patients, age 40 years and older, 43 of whom had
pre-existing arrhythmias, are reported. Cancer diagnoses were pre-
dominantly leukemia, lymphoma and multiple myeloma. Only
symptomatic arrhythmias and those requiring a change in medical
management were included.
Patients with pre-existing arrhythmias were more likely to experi-
ence transplant arrhythmias (38.6% vs 5.1%, p 5\0.0001), pre-
dominantly atrial fibrillation and atrial flutter. They were more
likely to be admitted to the ICU (22.7% vs 9.5%, p 5 0.009) and
had longer hospital stays (33.9 6 24.9 days vs 28.1 6 18.1 days, p
5 0.037). In-hospital death and death within one year of transplan-
tation were more frequent in patients with pre-existing arrhythmias
(22.7% vs 4.3%, p 5\0.0001 and 36.4% vs 16.3%, p 5 0.002, re-
spectively).
Transplant arrhythmias in patients with no prior history of ar-
rhythmias were also analyzed. These were predominantly atrial fi-
brillation and atrial flutter. Patients who experienced arrhythmias
were older, but did not have conventional risk factors for cardiac dis-
ease more frequently than those who did not experience arrhythmias.
Arrhythmias were more frequent with bone marrow transplantation
(BMT) compared to peripheral blood stem cell transplantation
(13.9% vs. 4.85%, p 5 0.033), though the numbers of patients un-
dergoing BMT was small, and with allogeneic transplantation com-
pared to autologous (7.98% vs. 3.57%, p 5 0.002). Arrhythmias
during transplantation were associated with poorer outcomes. Pa-
tients who experienced arrhythmias were more likely to be admitted
to the ICU (51.61% vs 7.22%, p 5\.001) and to have longer hos-
pital stays (40.986 24.86 vs 27.356 17.39, p5\.001). Both in-hos-
pital mortality and death within one year of transplantation were
higher (27.43% vs 3.05%, p\0.001 and 41.94% vs 14.9%,
p\0.001, respectively).Overall, transplant arrhythmias correlated with increasedmorbid-
ity and mortality. Though this study is limited by small numbers and
retrospective data, the cumulative evidence suggests prospective
studies and possibly more aggressive management of arrhythmias
during transplantation may be warranted.96
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After allogeneic HCT, 14 - 17% of patients die primarily due to
infections. The impact of AMI on transplant outcome and risk fac-
tors for AMI has not been well assessed in the current era of anti-
fungal agents. To assess this, the CIBMTR analyzed characteristics
and outcomes of patients receiving allogeneic HCT from 1995 -
2008. Cases (n 5 124) had a Zygomycetes [n 5 72 (58%)] or Fu-
sarium [n 5 52 (42%)] AMI between day 0 - 365 after HCT. A
control (ctl) cohort (n 5 11856) included all patients from the
same 66 centers as cases. HCT indication was malignancy in 106
(85%) cases and 9603 (81%) ctl. The median (range) follow-up
of cases and ctl is 61 (13 – 132) and 62 months (1 – 186), respec-
tively. Cases were older [41 yrs (1 – 68) vs 34 yrs (1 – 79); p 5
0.004] and more likely to have a KPS \90% at HCT [cases 5
50 (40%); ctl 5 3330 (28%); p 5 0.009]. Similar numbers of cases
occurred before and after May 2002 when voriconazole was FDA
approved [1995 – Apr 2002 5 60 (48%); May 2002 – 2008 5 64
(52%)]. Systemic antifungal prophylaxis (Table 1) was similar be-
tween cases and ctl (p 5 0.64). The median time from HCT
to AMI was 48 days (0 – 363) with most occurring between day
0 – 100 [day 0 – 30 5 49 (40%); day 31 – 60 5 18 (15%); day
61 – 100 5 22 (18%)]. AMI diagnosis significantly impacted 1-
year survival (OS) with a probability (95% CI) for cases of only
22% (15 – 29) compared to 65% (64 – 65) for ctl [p \0.001].
OS after the diagnosis of AMI was dismal at 52% (42 – 60) by
30 days following AMI and 27% (20 – 35) by day 100. In multivar-
iate analysis of OS, AMI increased the risk of death 6-fold
(p\0.0001) regardless of the site (Blood, GI, Respiratory, Other)
or the timing of infection. Compared to ctl, AMI beyond 100
days resulted in inferior survival vs AMI between day 0 - 30 [RR
of death 11.78 (7.76 – 17.87) vs 5.67 (4.14 – 7.77); p 5 0.006].
In multivariate analysis, time dependent factors occurring before
and which increase the risk of AMI include grade II – IV acute
GVHD [1.71 (1.13 – 2.58), p 5 0.01], chronic GVHD [2.40
(1.21 – 4.75), p 5 0.01], and prior Aspergillus infection [7.29
(3.70 – 13.38), p\0.001]. The only other significant factor for de-
veloping AMI was KPS \90% [1.92 (1.34 – 2.77), p 5 0.0004].
Year of HCT, co-morbid conditions, stem cell source, disease/dis-
ease status, age, donor/recipient CMV serostatus and conditioning
intensity were not significant. In conclusion, AMI occurs infre-
quently but appears similar in the current antifungal era and
remains associated with high morbidity.
Table. Antifungal Prophylaxis reported in Cases with AMI and
Controls
Antifungal Agent Cases [N(%)] Controls [N(%)]None 19 (15) 2000 (17)
Fluconazole 57 (46) 6264 (53)
Amphotericin 27 (22) 1782 (15)
Voriconazole 9 (7) 683 (6)
Echinocandin 1 (<1) 158 (1)
Other, including trials 11 (9) 969 (8)
